Sign In
Buy BWAY
$14.39
+0.0100 (+0.0695%)
At Close: Jun 23, 2026
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
07:30am, Monday, 22'nd Jun 2026
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulatio
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
07:30am, Tuesday, 09'th Jun 2026
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0% Preliminary Data Analysis Reveals O
BrainsWay Announces Minority-Stake Investment in Hopemark Health
07:30am, Monday, 18'th May 2026
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access t
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript
11:20am, Wednesday, 13'th May 2026
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript
Brainsway Q1 Earnings Call Highlights
10:08am, Wednesday, 13'th May 2026
Brainsway NASDAQ: BWAY reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recur
BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
07:30am, Wednesday, 13'th May 2026
R evenue grew approximately 35 % y ear- o ver- y ear to $1 5 .5 million for Q1 2026
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
10:40am, Monday, 04'th May 2026
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.
Recent Price Trend in Brainsway (BWAY) is Your Friend, Here's Why
09:56am, Wednesday, 29'th Apr 2026
Brainsway (BWAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026
08:00am, Wednesday, 29'th Apr 2026
BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio
4 Medical Product Stocks to Buy From a Challenging Industry
09:31am, Monday, 27'th Apr 2026
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
BrainsWay: Competitive Threats Are Mounting
10:29am, Friday, 24'th Apr 2026
BrainsWay continues to deliver strong growth and margin improvement, supported by investments in TMS service providers and recurring revenue expansion. BWAY's accelerated protocol and expanded indicat
BrainsWay Ltd (BWAY) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 68/100
06:10pm, Wednesday, 22'nd Apr 2026
On April 22, 2026, BrainsWay Ltd (BWAY) shares rose 3.4% today, bringing the current price to $15.85. The stock has seen significant upward movement in the past
BrainsWay Ltd (BWAY) Shares Fall 3.0% -- GF Value Says Still Overvalued
07:21pm, Thursday, 16'th Apr 2026
On April 16, 2026, BrainsWay Ltd (BWAY) shares fell 3.0% today to a current price of $15.33. Over the past year, the stock has seen a remarkable increase of 267
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
07:30am, Wednesday, 15'th Apr 2026
Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments Growing payer acceptance of nurse practitioner administrat
Brainsway (BWAY) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Monday, 13'th Apr 2026
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
